Vaccines Market Research Reports & Industry Analysis
Because of the large number of deadly diseases that have been eliminated through the proliferation of effective vaccines, vaccination is generally viewed as one of the greatest public health achievements of the 20th century. Key issues in the global vaccine market today include unequal access to vaccines, supply chain disruptions, the use of vaccines to prevent pandemics and address bioterrorism, technological innovations, and vaccine hesitancy. Learn more about this critical field with the comprehensive selection of vaccine market research reports available on MarketResearch.com.
New Vaccines Market Data and Insights
- Find data on vaccine market size segmented by region, technology, distribution channel, type, route of administration, and disease.
- Gain a deep understanding of vaccine industry dynamics, market structure, growth outlook, and competitive landscape.
- Learn about influential government initiatives and new vaccination technologies that have highly promising results.
Your Source for Expert Data and Analysis
MarketResearch.com is a trusted research partner, backed by over two decades of experience. Our clients include top investment banks, management consulting firms, and leading multinational companies within the Fortune 500. Our team of research specialists is dedicated to guiding you at every step, ensuring you have the resources and insights you need to answer your toughest research questions. Browse our full list of vaccines industry reports today.
Vaccines Industry Research & Market Reports
-
Microcarriers Market by Product (Equipment (Single Use Bioreactor, SSB, Cell Counter, Filtration), Consumables (Media, Reagent), Beads (Natural (Collagen), Synthetic (Polystyrene)), Application (Vaccine, CGT, Stem Cells) - Global Forecast to 2029
... to the growth of the microcarriers market are rising investments in cell & gene therapy research, technological advancement in in microcarrier-based cell production and increasing applications of microcarrier in vaccines and therapeutics development. Furthermore, limitations ... Read More
-
Middle East & Africa Human Vaccine Market Research Report Information by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Route of Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Industry Forecast to 2032
... a specific illness, thereby protecting people from infection and its potentially serious effects. These vaccines often contain weakened or dead organisms (such as viruses or bacteria), toxins, or surface proteins that elicit an immune response ... Read More
-
Recombinant Dna Technology Market, By Product Type (Recombinant Protein Drugs, Vaccines , Genetically Modified Crops, Cell and Gene Therapy, and Gene Editing), By Application (Therapeutics, Agriculture, Research, and Others), By End User (Biotechnology and Pharmaceutical Company, Diagnostic Laboratories, Academic and Government Institutes, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
... joining together of DNA molecules from two different sources into one molecule that can replicate and direct the assembly of its own components or related proteins. This process involves physically combining and interweaving two different ... Read More
-
Veterinary Vaccines Market, By Animal Type (Companion, Livestock), By Technology (Inactivated Vaccines, Toxoid Vaccines, Live Attenuated Vaccines, Subunit and DNA Vaccines, and Recombinant Vaccines), By Route of Administration (Subcutaneous Injection, Intramuscular Injection, Intranasal Administration, and Others), By Distribution Channel (Public and Private), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
... to animals in order to stimulate the immune system and provide active immunity against a disease. Vaccination protects individual animals from infectious diseases and generates herd immunity which indirectly protects the whole community. The global ... Read More
-
Respiratory Disease Vaccine Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
... asthma, COPD, and influenza, has driven demand for preventive solutions such as vaccines. Rising global awareness of respiratory health, especially after the recent pandemic, has pushed governments and healthcare organizations to prioritize immunization efforts. With ... Read More
-
H1N1 Vaccines Market Report by Vaccine Type (Intramuscular, Intranasal, Intradermal), Market Type (Public, Private), and Region 2025-2033
... The increasing healthcare concerns, significant medical advancements, improving healthcare systems, and rising awareness about the importance of H1N1 vaccines are some of the major factors propelling the market. H1N1 vaccines, also known as influenza A ... Read More
-
Pharmaceutical Contract Packaging Market Report by Industry (Small Molecule, Biopharmaceutical, Vaccine), Type (Sterile, Non-sterile), Packaging (Plastic Bottles, Caps and Closures, Blister Packs, Prefilled Syringes, Parenteral Vials and Ampoules, and Others), and Region 2025-2033
... 2025-2033. The increasing outsourcing trends, rising demand for medications and medical devices, stringent regulatory compliance, product diversification and cost-effectiveness, significant technological advancements, and increasing environmental considerations are some of the major factors propelling the market. ... Read More
-
U.S. Sterile Injectables Market, By Molecule Type (Large Molecule and Small Molecule), By Drug Type (Monoclonal Antibody (mAbs), Cytokines, Insulin, Peptide Hormones, Vaccines, and Others), By Therapeutic Application (Cancer, Metabolic Disorder, Cardiovascular Diseases, Infectious Diseases, Musculoskeletal Disorders, and Others), By Route of Administration (Subcutaneous, Intravenous, Intramuscular, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
... that are administered via various injection routes such as intravenous, intramuscular, subcutaneous, and others in their final sterile form for healing or preventing medical conditions. The rising prevalence of chronic diseases like cancer, diabetes, autoimmune ... Read More
-
Global Dengue Vaccines Industry Growth and Trends Forecast to 2031
... recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in ... Read More
-
Global Dengue Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
... recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in ... Read More
-
Dengue Vaccines Industry Research Report 2025
... recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in ... Read More
-
mRNA Platform
... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine Indication, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the ... Read More
-
Dengue Vaccine
... CAGR of 15.9% over the analysis period 2024-2030. Government Institutions End-Use, one of the segments analyzed in the report, is expected to record a 14.3% CAGR and reach US$774.6 Million by the end of the ... Read More
-
Meningococcal Vaccines
... CAGR of 4.8% over the analysis period 2024-2030. Quadrivalent Vaccines, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$3.1 Billion by the end of the analysis ... Read More
-
Porcine Vaccines
... CAGR of 4.9% over the analysis period 2024-2030. Inactivated Vaccines Technology, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$1.2 Billion by the end of the ... Read More
-
Shingles Vaccines
... CAGR of 4.9% over the analysis period 2024-2030. Recombinant Vaccines, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$3.9 Billion by the end of the analysis ... Read More
-
Vaccine Adjuvants
... CAGR of 9.1% over the analysis period 2024-2030. Particulate Adjuvants, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$562.7 Million by the end of the analysis ... Read More
-
Therapeutic Vaccines
... CAGR of 16.7% over the analysis period 2024-2030. Autoimmune Disease Vaccines, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$62.8 Billion by the end of the ... Read More
-
Foot and Mouth Disease (FMD) Vaccine
... reach US$5.6 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. Conventional Vaccines, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach ... Read More
-
H1N1 Vaccines
... CAGR of 5.4% over the analysis period 2024-2030. Intramuscular Vaccines, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$1.1 Billion by the end of the analysis ... Read More
-
Pediatric Drugs and Vaccines
... 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Conjugate Technology, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$52.0 Billion by the ... Read More
-
Veterinary Vaccines
... CAGR of 5.6% over the analysis period 2024-2030. Porcine Vaccines, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$4.7 Billion by the end of the analysis ... Read More
-
Human Vaccines
... CAGR of 7.3% over the analysis period 2024-2030. Intramuscular & Subcutaneous Administration, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$58.7 Billion by the end of ... Read More
-
Preventable Vaccines
... CAGR of 1.1% over the analysis period 2024-2030. Live / Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 1.2% CAGR and reach US$34.1 Billion by the end of ... Read More
-
Cancer Vaccines
... CAGR of 9.3% over the analysis period 2024-2030. Preventive Vaccine, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$7.6 Billion by the end of the analysis ... Read More
Research Assistance
